Comment on administration and scoring of the Neuropsychiatric Inventory in clinical trials

Authors

Donald J. Connor, Banner Sun Health Research Institute
Marwan N. Sabbagh, Banner Sun Health Research InstituteFollow
Jeffery L. Cummings, David Geffen School of Medicine at UCLA

Document Type

Editorial

Abstract

Background: The Neuropsychiatric Inventory (NPI) is commonly used in dementia trials to quantify and qualitate changes in psychiatric symptoms. Methods: A questionnaire was administered to clinical trial raters to assess whether they were being trained to administer and score the NPI differently between clinical trial protocols. Results: Responses to the survey indicated that there are differences between clinical trials protocols in how the instrument is administered and scored. Discussion: Clarification of administration and scoring rules are provided, including the behavioral sampling period, whether premorbid characteristics are considered, and what behaviors are considered in rating frequency, severity, and caregiver distress. © 2008 The Alzheimer's Association.

Publication Date

11-1-2008

Publication Title

Alzheimer's and Dementia

ISSN

15525260

Volume

4

Issue

6

First Page

390

Last Page

394

PubMed ID

19012863

Digital Object Identifier (DOI)

10.1016/j.jalz.2008.09.002

Recommended Citation

Connor, Donald J.; Sabbagh, Marwan N.; and Cummings, Jeffery L., "Comment on administration and scoring of the Neuropsychiatric Inventory in clinical trials" (2008). Neurology. 819.
https://scholar.barrowneuro.org/neurology/819